| Bookmarkers beware: Bookmarks to pages other than the home page may not work after we change our server in April |
Editor's Choice | This Week in BMJ | Press releases
BMJ No 7133 Volume 316
Editorial Saturday 7 March 1998
Hydroxychloroquine retinopathy: is screening necessary?
Intensive screening is not necessary at normal doses
The 4-aminoquinolines (chloroquine and hydroxychloroquine) are used as second line agents for their disease modifying effect in rheumatoid arthritis and systemic lupus erythematosus. The association between chloroquine therapy and pigmentary maculopathy has been known since 1959.(1) The manufacturer's datasheet suggests that all patients receiving hydroxychloroquine should undergo an ophthalmic examination, including a central visual field test, at least twice a year. If implemented this recommendation would have a noticeable impact on the ophthalmic service. Is it necessary?
The earliest sign of chloroquine retinopathy is a paracentral scotoma. This so called premaculopathy can be detected with an Amsler chart.(2) Later, subtle pigmentary mottling develops at the macula, and this may progress to the characteristic bull's eye maculopathy and widespread retinal pigment epithelial atrophy. In its early stages chloroquine retinopathy is reversible by stopping the drug.(3) Hydroxychloroquine given at currently prescribed doses is thought to be less toxic than chloroquine.
The recommended dose for hydroxychloroquine is 6.5 mg/kg lean body weight per day.(4) In their prospective study of 73 patients treated with hydroxychloroquine for at least 18 months, Morsman et al reported one case of possible toxic retinopathy - and this patient had received twice the recommended daily dose.(5) In a retrospective study of 82 patients taking hydroxychloroquine for over a year (mean 38.6 months) Spalton et al found no cases of retinopathy.(6) No correlation was present between the computerised visual field indices and any measure of increasing drug exposure. The authors concluded that visual field testing was unnecessary in these patients.(6) Bernstein analysed all published cases and Food and Drug Administration reports of hydroxychloroquine retinopathy. He found no evidence of permanent visual loss among more than 1,500 patients who did not exceed the recommended daily dosage for up to 10 years.(7) More recently, however, two well documented cases of hydroxychloroquine retinopathy have been reported in patients treated for 6.5 and 8 years without exceeding the recommended maximum daily dose.(8)
The Royal College of Ophthalmologists' guidelines for managing
patients receiving hydroxychloroquine recommend a baseline ophthalmic
examination at the start of treatment, including best corrected visual
acuity, fundoscopy, and a central visual field test.(9)
Thereafter the prescribing medical practitioner should be responsible
for any screening considered necessary. Patients should be warned to
report any visual disturbance and may be given an Amsler chart to
use on a monthly basis. No further ophthalmic examination is
necessary unless the patient becomes symptomatic. Current evidence suggests that hydroxychloroquine retinopathy
is extremely rare if the recommended dose is not exceeded. In most
cases a baseline ophthalmic assessment and issue of an Amsler chart
with instructions on its use will suffice. The small number of patients
who have received hydroxychloroquine for longer than six years should
be kept under ophthalmic review until more information is available
about the safety of long term treatment.
Chris Blyth
Carol Lane
References
1 Hobbs H E, Sorsby A, Freedman A. Retinopathy following
chloroquine therapy. Lancet 1959;ii:478-80.
2 Easterbrook M. The sensitivity of Amsler grid testing in early
chloroquine retinopathy. Trans Ophthalmol Soc UK
1985;104:204-7.
3 Crews S J. Chloroquine retinopathy with recovery in early
stages. Lancet 1964;ii:436-8.
4 Mackenzie A H. Dose refinements in long-term therapy of
rheumatoid arthritis with antimalarials. Am J Med
1983;75(suppl):40-5.
5 Morsman C D G, Livesey S J, Richards I M, Jessop J D, Mills P V.
Screening for hydroxychloroquine retinal toxicity: is it necessary?
Eye 1990;4:572-6.
6 Spalton D J, Roe G M V, Hughes G R V. Hydroxychloroquine, dosage
parameters and retinopathy. Lupus 1993;2:355-8.
7 Bernstein H N. Ocular safety of hydroxychloroquine. Ann
Ophthalmol 1991;23:292-6.
8 Mavrikakis M, Papazoglou S, Sfikakis P P, Vaiopoulos G, Rougas
K. Retinal toxicity in long term hydroxychloroquine treatment.
Ann Rheum Dis 1996;55:187-9.
9 Royal College of Ophthalmologists. Chloroquine,
hydroxychloroquine and the eye. London: RCO,
1993.
Senior registrar in ophthalmology
Consultant ophthalmologist
Cardiff Eye Unit,
University Hospital of Wales Healthcare NHS
Trust,
Cardiff CF4
4XW
Home | Current issue | Past issues | Classified ads | Career Focus | Feedback
Collections | About this site | About the BMJ | BMA | Medline